{
    "root": "2fb33cad-68d5-7110-e063-6394a90ab175",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sertraline Hydrochloride",
    "value": "20250306",
    "ingredients": [
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "SERTRALINE HYDROCHLORIDE",
            "code": "UTI8907Y6X"
        }
    ],
    "indications": "sertraline hydrochloride tablets indicated treatment following [ ( 14 ) ] : major depressive disorder ( mdd ) obsessive-compulsive disorder ( ocd ) panic disorder ( pd ) posttraumatic stress disorder ( ptsd ) social anxiety disorder ( sad ) premenstrual dysphoric disorder ( pmdd )",
    "contraindications": "­indication starting maximum mdd ( 2.1 ) 50 mg per day 200 mg per day ocd ( 2.1 ) 25 mg per day ( ages 6 12 ) 50 mg per day ( ages ≥ 13 ) 200 mg per day pd , ptsd , sad ( 2.1 ) 25 mg per day 200 mg per day pmdd ( 2.2 ) continuous dosing 50 mg per day 150 mg per day pmdd ( 2.2 ) intermittent dosing 50 mg per day luteal phase 100 mg per day luteal phase inadequate response starting , titrate 25 50 mg per day increments weekly mdd , ocd , pd , ptsd , sad ( 2.1 ) full prescribing information titration pmdd ( 2.2 ) hepatic impairment : mild : recommended starting maximum half recommended ( 2.4 ) moderate severe : recommended ( 2.4 ) discontinuing sertraline hydrochloride tablets , reduce dose gradually ( 2.6 , 5.4 )",
    "warningsAndPrecautions": "sertraline hydrochloride tablets usp , 25 mgare green colored , biconvex , capsule shaped film coated tablets debossed ‘ ’ one side score line ‘ 1 ’ ‘ 6 ’ side . ndc 65862-011-30 bottles 30 ndc 65862-011-50 bottles 50 ndc 65862-011-60 bottles 60 ndc 65862-011-90 bottles 90 ndc 65862-011-01 bottles 100 ndc 65862-011-05 bottles 500 ndc 65862-011-99 bottles 1,000 ndc 65862-011-51 bottles 5,000 sertraline hydrochloride tablets usp , 50 mgare blue colored , biconvex , capsule shaped film coated tablets debossed ‘ ’ one side score line ‘ 1 ’ ‘ 7 ’ side . ndc 65862-012-30 bottles 30 ndc 65862-012-50 bottles 50 ndc 65862-012-60 bottles 60 ndc 65862-012-90 bottles 90 ndc 65862-012-01 bottles 100 ndc 65862-012-05 bottles 500 ndc 65862-012-99 bottles 1,000 ndc 65862-012-51 bottles 5,000 sertraline hydrochloride tablets usp , 100 mg yellow colored , biconvex , capsule shaped film coated tablets debossed ‘ ’ one side score line ‘ 1 ’ ‘ 8 ’ side . ndc 65862-013-30 bottles 30 ndc 65862-013-50 bottles 50 ndc 65862-013-60 bottles 60 ndc 65862-013-90 bottles 90 ndc 65862-013-01 bottles 100 ndc 65862-013-05 bottles 500 ndc 65862-013-99 bottles 1,000 ndc 65862-013-25 bottles 2,500 store 20º 25ºc ( 68º 77ºf ) ; excursions permitted 15º 30ºc ( 59° 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "sertraline hydrochloride tablets contraindicated patients : taking , within 14 days stopping , maois , ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.2 ) , ( 7.1 ) ] . taking pimozide [ ( 7.1 ) ] . known hypersensitivity sertraline ( e.g . , anaphylaxis , angioedema ) [ ( 6.1 , 6.2 ) ] .",
    "indications_original": "Sertraline hydrochloride tablets are indicated for the treatment of the following\n \n  [See\n  \n   Clinical Studies (14)]\n \n  :\n\n \n                  \n                  \n                     Major depressive disorder (MDD)\n                     Obsessive-compulsive disorder (OCD)\n                     Panic disorder (PD)\n                     Posttraumatic stress disorder (PTSD)\n                     Social anxiety disorder (SAD)\n                     Premenstrual dysphoric disorder (PMDD)",
    "contraindications_original": "­Indication Starting Dosage Maximum Dosage MDD ( 2.1 ) 50 mg per day 200 mg per day OCD ( 2.1 ) 25 mg per day (ages 6 to 12) 50 mg per day (ages ≥ 13) 200 mg per day PD, PTSD, SAD ( 2.1 ) 25 mg per day 200 mg per day PMDD ( 2.2 ) continuous dosing 50 mg per day 150 mg per day PMDD ( 2.2 ) intermittent dosing 50 mg per day during luteal phase only 100 mg per day during luteal phase only If inadequate response to starting dosage, titrate in 25 to 50 mg per day increments once weekly in MDD, OCD, PD, PTSD, and SAD ( 2.1 ) See Full Prescribing Information for titration in PMDD ( 2.2 ) Hepatic impairment: Mild: Recommended starting and maximum dosage is half recommended dosage ( 2.4 ) Moderate or severe: Not recommended ( 2.4 ) When discontinuing sertraline hydrochloride tablets, reduce dose gradually ( 2.6 , 5.4 )",
    "warningsAndPrecautions_original": "Sertraline Hydrochloride Tablets USP, 25 mgare green colored, biconvex, capsule shaped film coated tablets debossed with ‘A’ on one side and with a score line in between ‘1’ and ‘6’ on the other side. \n  \n                       NDC 65862-011-30                            Bottles of 30 \n    NDC 65862-011-50                            Bottles of 50 \n    NDC 65862-011-60                            Bottles of 60 \n    NDC 65862-011-90                            Bottles of 90 \n    NDC 65862-011-01                            Bottles of 100 \n    NDC 65862-011-05                            Bottles of 500 \n    NDC 65862-011-99                            Bottles of 1,000 \n    NDC 65862-011-51                            Bottles of 5,000 \n  \n                     \n                          Sertraline Hydrochloride Tablets USP,\n  \n                     50 mgare blue colored, biconvex, capsule shaped film coated tablets debossed with ‘A’ on one side and with a score line in between ‘1’ and ‘7’ on the other side. \n  \n                       NDC 65862-012-30                            Bottles of 30 \n    NDC 65862-012-50                            Bottles of 50 \n    NDC 65862-012-60                            Bottles of 60 \n    NDC 65862-012-90                            Bottles of 90 \n    NDC 65862-012-01                            Bottles of 100 \n    NDC 65862-012-05                            Bottles of 500 \n    NDC 65862-012-99                            Bottles of 1,000 \n    NDC 65862-012-51                            Bottles of 5,000 \n  \n                     \n                     Sertraline Hydrochloride Tablets USP, 100 mg are yellow colored, biconvex, capsule shaped film coated tablets debossed with ‘A’ on one side and with a score line in between ‘1’ and ‘8’ on the other side. \n  \n                       NDC 65862-013-30                            Bottles of 30 \n    NDC 65862-013-50                            Bottles of 50 \n    NDC 65862-013-60                            Bottles of 60 \n    NDC 65862-013-90                            Bottles of 90 \n    NDC 65862-013-01                            Bottles of 100 \n    NDC 65862-013-05                            Bottles of 500 \n    NDC 65862-013-99                            Bottles of 1,000 \n    NDC 65862-013-25                            Bottles of 2,500 \n  \n                     \n                          Store at\n  20º to 25ºC(68º to 77ºF); excursions permitted to 15º to 30ºC (59° to 86°F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Sertraline hydrochloride tablets are contraindicated in patients:\n                  \n                     Taking, or within 14 days of stopping, MAOIs, (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome\n  \n   [See\n   \n    Warnings and Precautions (5.2),\n   \n    Drug Interactions (7.1)]\n  \n   .\n \n  \n                     Taking pimozide\n  \n   [See\n   \n    Drug Interactions (7.1)]\n  \n   .\n \n  \n                     With known hypersensitivity to sertraline (e.g., anaphylaxis, angioedema)\n  \n   [See\n   \n    Adverse Reactions (6.1,\n   \n    6.2)]."
}